PPD to Expand GMP Lab in Ireland to Enhance Biopharmaceutical Testing Capabilities
Adding cell and gene therapy capabilities to support growing customer need
WILMINGTON, N.C. (April 28, 2021) –
The expansion enhances PPD’s ability to deliver global scientific and technical expertise to meet growing customer demand in
“Our enlarged operations will enhance our capabilities in leading technologies related to biopharmaceutical testing and specialty testing for biologics and small molecules,” said
The Athlone GMP lab provides fully integrated analytical services across all phases of pharmaceutical development and commercialization, helping clients fulfill regulatory requirements for release testing and qualified person (QP) services for clinical and marketed pharmaceuticals, including small and large molecules, inhaled products, and cell and gene therapies.
The current 4,460 sq. meter (48,000 sq. foot) operation will grow to 7,710 sq. meters (83,000 sq. feet) upon completion of the project, which is expected to be fully functional by mid-2022 and is projected to create 180 new jobs over the next three years. The current operation employs nearly 300 highly skilled scientists and project managers who support the demand for PPD’s services, which includes testing to support the development of novel and advanced pharmaceuticals and therapies.
Tánaiste and Minister for Enterprise Trade and Employment
Minister of State at the
CEO of IDA Ireland Martin Shanahan added: “Today’s announcement by PPD demonstrates the company’s commitment to
In addition to the lab in Athlone,
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 27,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; the risks related to the planned acquisition of PPD by Thermo Fisher Scientific Inc.; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the